{"title": "Neurolog\u00eda.com", "author": "Viguera Editores", "url": null, "hostname": null, "description": "Neurolog\u00eda.com", "sitename": null, "date": "2018-04-13", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "|\n|\nTabla I. Ensayos cl\u00ednicos en fase II y III de ocrelizumab.\n|\n||\n|\nCaracter\u00edsticas\n|\n|\nCriterios de inclusi\u00f3n\n|\n|\nObjetivo primario\n|\n|\n\u00bfCumpli\u00f3 el objetivo primario?\n|\n|\nNCT00676715\n(WA21493)\n|\n|\nOCR 600 mg frente a OCR 2.000 mg\nfrente a Avonex frente a placebo (1:1:1:1)\nFase II\n|\n|\nEMRR\nEDSS: 1-6,6\n\u2265 2 brotes en los tres a\u00f1os previos\n(1 brote en el a\u00f1o previo)\n\u2265 6 lesiones en T2\n|\n|\nN.\u00ba de lesiones captantes de gadolinio en T1 en la resonancia magn\u00e9tica\n|\n|\nS\u00ed\nOCR 600 mg: \u2193 89% (IC 95%: 68-97%)\nOCR 2.000 mg: \u2193 96% (IC 95%: 89-99%)\np < 0,0001\n|\n|\nNCT01412333 (OPERA I/II)\n|\n|\nOCR 600 mg frente a Rebif 44 \u00b5g (1:1)\nFase III\n|\n|\nEMRR\nEDSS: 0-5,5\n\u2265 2 brotes en los dos a\u00f1os previos,\no un brote en el a\u00f1o previo\n|\n|\nTasa anualizada de\nbrotes en 96 semanas\n|\n|\nS\u00ed\nOPERA I: \u2193 46% (IC 95%: 28-60%)\nOPERA II: \u2193 47% (IC 95%: 29-60%)\np < 0,001\n|\n|\nNCT01194570 (ORATORIO)\n|\n|\nOCR 600 mg frente a placebo (2:1)\nFase III\n|\n|\nEMPP\nEDSS: 3-6,5\nSi EDSS > 5: < 15 a\u00f1os\nSi EDSS \u2264 5: < 10 a\u00f1os\n|\n|\nIncremento de la EDSS\nmantenido en 12 semanas\n|\n|\nS\u00ed\nOCR 600 mg: \u2193 24% (IC 95%: 2-41%)\np = 0,03\n|\n|\nNCT03085810\n|\n|\nOCR en na\u00efve (grupo \u00fanico)\nFase III\nOpen label\n|\n|\nEMRR \u2264 3 a\u00f1os\nEDSS: 0-3,5\nActividad cl\u00ednica o radiol\u00f3gica\nen los \u00faltimos 12 meses\n|\n|\nTiempo hasta discapacidad confirmada en 24 y 48 semanas\n|\n|\nOngoing\n|\n|\nNCT02637856\n|\n|\nOCR en refractarios (grupo \u00fanico)\nFase III\nOpen label\n|\n|\nEMRR \u2264 12 a\u00f1os\n\u2264 3 FME previos durante \u2265 6 meses\nSuspendi\u00f3 el \u00faltimo por ineficacia\n|\n|\nNEDA\n|\n|\nOngoing\n|\n|\nEDSS: Expanded Disability Status Scale; EMPP: esclerosis m\u00faltiple primariamente progresiva; EMRR: esclerosis m\u00faltiple remitente recurrente; FME: f\u00e1rmaco modificador de la enfermedad; NEDA: no evidence of disease activity; OCR: ocrelizumab.", "language": null, "image": "https://neurologia.com/img/logos/logo_social.jpg", "pagetype": "website", "links": ["https://neurologia.com/", "https://neurologia.com/", "#", "revista", "revista-sociedades", "comite-editorial", "responsabilidades", "gestion/contacta", "gestion/enviar-manuscrito", "basicos", "gestion/estado-articulo", "#", "https://neurologia.com/revista/77/06", "revista", "revista-sociedades", "comite-editorial", "responsabilidades", "gestion/contacta", "gestion/enviar-manuscrito", "basicos", "gestion/estado-articulo", "revisores", "#", "noticias", "podcast", "revista/casos-clinicos", "revista/comunicados-sociedades", "entrevistas", "separatas", "anuncios", "patrocinio", "#", "noticias", "podcast", "revista/casos-clinicos", "revista/comunicados-sociedades", "entrevistas", "separatas", "anuncios", "patrocinio", "agenda", "#", "", "https://www.ineurocampus.com", "https://www.ineurocampus.com/master-en-trastornos-del-movimiento.html", "https://www.ineurocampus.com/master-en-neurociencia-experimental-y-clinica.html", "https://www.ineurocampus.com/master-en-neuroinmunologia.html", "https://www.ineurocampus.com/master-en-sueno-fisiologia-y-medicina.html", "https://www.ineurocampus.com/master-en-epilepsia.html", "https://www.ineurocampus.com/master-en-neuropsicologia-de-las-altas-capacidades-intelectuales.html", "https://www.ineurocampus.com/master-en-trastornos-del-espectro-autista.html", "https://www.ineurocampus.com/master-en-psicobiologia-y-neurociencia-cognitiva.html", "#", "", "https://www.ineurocampus.com", "https://www.ineurocampus.com/master-en-trastornos-del-movimiento.html", "https://www.ineurocampus.com/master-en-neurociencia-experimental-y-clinica.html", "https://www.ineurocampus.com/master-en-neuroinmunologia.html", "https://www.ineurocampus.com/master-en-sueno-fisiologia-y-medicina.html", "https://www.ineurocampus.com/master-en-epilepsia.html", "https://www.ineurocampus.com/master-en-neuropsicologia-de-las-altas-capacidades-intelectuales.html", "https://www.ineurocampus.com/master-en-trastornos-del-espectro-autista.html", "https://www.ineurocampus.com/master-en-psicobiologia-y-neurociencia-cognitiva.html", "#", null, "", "https://neurologia.com/articulo/2018132/esp", "https://neurologia.com/articulo/2018132/eng", "https://neurologia.com/autor/45812/a-juanatey", "https://neurologia.com/autor/45813/l-blanco-garcia", "https://neurologia.com/autor/40376/n-tellez", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=29897610&itool=iconfft", "https://doi.org/10.33588/rn.6612.2018132", null, null, null, null, "https://www.facebook.com/sharer/sharer.php?u=https://neurologia.com/articulo/2018132", "https://twitter.com/intent/tweet?url=https://neurologia.com/articulo/2018132&text=Ocrelizumab: eficacia y seguridad en la esclerosis m\u00faltiple", "https://neurologia.com/articulo/2018132/esp#info_introducci\u00f3n", "https://neurologia.com/articulo/2018132/esp#info_desarrollo", "https://neurologia.com/articulo/2018132/esp#info_c\u00e9lulas-b-como-diana-terap\u00e9utica-en-la-em", "https://neurologia.com/articulo/2018132/esp#info_anticuerpos-anti-cd20", "https://neurologia.com/articulo/2018132/esp#info_ocrelizumab-en-la-em-en-brotes-(emrr)", "https://neurologia.com/articulo/2018132/esp#info_monitorizaci\u00f3n-de-c\u00e9lulas-cd19+", "https://neurologia.com/articulo/2018132/esp#info_serolog\u00edas-y-vacunaciones", "https://neurologia.com/articulo/2018132/esp#info_seguridad", "https://neurologia.com/articulo/2018132/esp#info_reacciones-a-la-infusi\u00f3n", "https://neurologia.com/articulo/2018132/esp#info_infecciones", "https://neurologia.com/articulo/2018132/esp#info_neoplasias", "https://neurologia.com/articulo/2018132/esp#info_otras", "https://neurologia.com/articulo/2018132/esp#info_embarazo", "https://neurologia.com/articulo/2018132/esp", "https://neurologia.com/articulo/2018132/eng", "https://neurologia.com/buscar/antigeno+cd20/p", "https://neurologia.com/buscar/esclerosis+multiple/p", "https://neurologia.com/buscar/esclerosis+multiple+primariamente+progresiva/p", "https://neurologia.com/buscar/esclerosis+multiple+remitente+recurrente/p", "https://neurologia.com/buscar/ocrelizumab/p", "https://neurologia.com/categoria/7a/esclerosis-multiple", "https://neurologia.com/articulo/2018132/esp", "https://neurologia.com/articulo/2018132/eng", null, "articulo/2018132#b01", "articulo/2018132#b02", "articulo/2018132#b03", "articulo/2018132#b05", "articulo/2018132#b07", "articulo/2018132#b08", "articulo/2018132#b09", "articulo/2018132#b10", "articulo/2018132#b11", "articulo/2018132#b12", "articulo/2018132#b15", "articulo/2018132#b16", "articulo/2018132#b17", "articulo/2018132#b17", "articulo/2018132#b18", "articulo/2018132#b19", "articulo/2018132#b20", null, null, "articulo/2018132#b21", "articulo/2018132#b22", "articulo/2018132#b23", "articulo/2018132#b24", "articulo/2018132#b25", "articulo/2018132#b26", null, "articulo/2018132#b18", null, "articulo/2018132#b27", "articulo/2018132#b28", "articulo/2018132#b29", "articulo/2018132#b30", "articulo/2018132#b31", "articulo/2018132#b32", "articulo/2018132#b18", "articulo/2018132#b33", "articulo/2018132#b33", null, "articulo/2018132#b33", null, "articulo/2018132#b34", null, "articulo/2018132#b35", "articulo/2018132#b28", "articulo/2018132#b36", "articulo/2018132#b28", "articulo/2018132#b33", "articulo/2018132#b20", "articulo/2018132#b37", null, "articulo/2018132#b20", "articulo/2018132#b38", "articulo/2018132#b39", null, "articulo/2018132#b27", "articulo/2018132#b24", "articulo/2018132#b28", "articulo/2018132#b33", "articulo/2018132#b40", null, "articulo/2018132#b28", "articulo/2018132#b38", "articulo/2018132#b28", "articulo/2018132#b33", "articulo/2018132#b41", "articulo/2018132#b28", "articulo/2018132#b38", null, "articulo/2018132#b28", "articulo/2018132#b33", "articulo/2018132#b40", "articulo/2018132#b20", null, "articulo/2018132#b28", "articulo/2018132#b33", "articulo/2018132#b42", "articulo/2018132#b42", null, "articulo/2018132#b43", "articulo/2018132#b40", null, "articulo/2018132#b44", "articulo/2018132#b44", "articulo/2018132#b45", "articulo/2018132#b46", "articulo/2018132#b46", "articulo/2018132#b47", "articulo/2018132#b47", "articulo/2018132#b48", "articulo/2018132#b15", "articulo/2018132#b49", "articulo/2018132#b50", "articulo/2018132#b51", "articulo/2018132#b52", "articulo/2018132#ref_b01", null, "articulo/2018132#ref_b02", null, "articulo/2018132#ref_b03", null, "articulo/2018132#ref_b04", null, "articulo/2018132#ref_b05", null, "articulo/2018132#ref_b06", null, "articulo/2018132#ref_b07", null, "articulo/2018132#ref_b08", null, "articulo/2018132#ref_b09", null, "articulo/2018132#ref_b10", null, "articulo/2018132#ref_b11", null, "articulo/2018132#ref_b12", null, "articulo/2018132#ref_b13", null, "articulo/2018132#ref_b14", null, "articulo/2018132#ref_b15", null, "articulo/2018132#ref_b16", null, "articulo/2018132#ref_b17", null, "articulo/2018132#ref_b18", null, "articulo/2018132#ref_b19", null, "articulo/2018132#ref_b20", null, "articulo/2018132#ref_b21", null, "articulo/2018132#ref_b22", null, "articulo/2018132#ref_b23", null, "articulo/2018132#ref_b24", null, "articulo/2018132#ref_b25", null, "articulo/2018132#ref_b26", null, "articulo/2018132#ref_b27", null, "articulo/2018132#ref_b28", null, "articulo/2018132#ref_b29", null, "articulo/2018132#ref_b30", null, "articulo/2018132#ref_b31", null, "articulo/2018132#ref_b32", null, "articulo/2018132#ref_b33", null, "articulo/2018132#ref_b34", null, "articulo/2018132#ref_b35", null, "articulo/2018132#ref_b36", null, "articulo/2018132#ref_b37", null, "articulo/2018132#ref_b38", null, "articulo/2018132#ref_b39", null, "articulo/2018132#ref_b40", null, "articulo/2018132#ref_b41", null, "articulo/2018132#ref_b42", null, "articulo/2018132#ref_b43", null, "articulo/2018132#ref_b44", null, "articulo/2018132#ref_b45", null, "articulo/2018132#ref_b46", null, "articulo/2018132#ref_b47", null, "articulo/2018132#ref_b48", null, "articulo/2018132#ref_b49", null, "articulo/2018132#ref_b50", null, "articulo/2018132#ref_b51", null, "articulo/2018132#ref_b52", null, "https://www.viguera.com/", "https://www.evidenze.com/", "https://ineurocampus.com/", "//stamp.wma.comb.es/es/seal/2735", "politica-privacidad", "aviso-legal", "cookies", "https://neurologia.com/", "revista", "agenda", "formacion", "https://www.linkedin.com/company/viguera", "https://twitter.com/RevNeurol", "https://www.facebook.com/RevNeurol", "https://wa.me/0034686590906", "https://t.me/Viguera_Editores"]}